Pancreas Cancer Specialized Program of Research Excelle*

描述（由申请人提供）： 胰腺癌卓越研究专业计划（SPORE）的目标是将优秀的假设驱动的基础研究转化为挽救生命的临床治疗。胰腺癌是一种毁灭性的癌症，不仅因为它可能极具侵略性，而且因为它被诊断为晚期，所以会杀死患者。该SPORE是乔治城大学，Geisinger Health System和德国研究所与德国医院联盟之间的独特合作，汇集了一个优秀的学术机构，一个大型区域医疗保健系统和德国基础和临床研究系统，以解决胰腺癌的生物学和临床护理。项目1的重点是抑制多效生长因子，一种新的肝素结合生长因子，促进胰腺癌的侵袭和转移。项目2的重点是神经调节素和多效生长因子在神经元肿瘤细胞相互作用的既定模型中的作用，其目标是开发阻断恶性胰腺细胞神经侵袭的方法，最终可能有助于缓解疾病。项目3的重点是最近的研究结果，即抑制胰腺癌细胞和邻近内皮细胞内的核受体辅激活因子AIB 1可能会阻断多种生长因子的信号传导，从而增强细胞凋亡。ras/MAP激酶通路的激活发生在高达90%的胰腺癌中，是项目4中放射增敏新方法的焦点。乔治城大学的研究人员已经开发出一种rafl反义抑制剂，该抑制剂已经进入I期试验，并开发了该途径中的其他互补分子靶点。 此外，该SPORE正在开发基础设施和资源，以获取患者的组织和体液（胰腺肿瘤库和血清检测和分子鉴定核心），预计每年可进行120例根治性切除术。SPORE将利用生物统计学核心，以确保所有项目都具有适当的设计、分析方法和用于报告患者结局的集成数据库。此外，SPORE将支持旨在产生早期检测新知识和方法的发展项目，并促进致力于胰腺癌转化研究的职业发展。该SPORE还与其他机构的SPORE以及其他NCI和NIH资助的项目建立互动，以促进胰腺癌控制新疗法的积极发展。

DESCRIPTION (provided by applicant): The goal of this Specialized Program of Research Excellence (SPORE) in pancreas cancer is to translate outstanding hypothesis-driven basic research into clinical treatment that saves lives. Pancreatic cancer is a devastating cancer that kills patients not just because it may be extremely aggressive but also because it is diagnosed late. This SPORE is a unique collaboration between Georgetown University, Geisinger Health System and INDIVUMED a German Research Institute with a German hospital consortium that brings together an outstanding academic institution, a large regional healthcare system and a German basic and clinical research system to address the biology of pancreatic cancer and clinical care. Project 1 focuses on inhibition of pleiotrophin, a novel heparin-binding growth factor that promotes invasion and metastasis in pancreatic cancer. Project 2 focuses on the role of neuregulins and pleiotrophin in an established model of neuron tumor cell interaction with the goal of developing methods to block neural invasion by malignant pancreas cells that may ultimately aid in disease palliation. Project 3 focuses on recent findings that inhibition of the nuclear receptor coactivator AIB1 within pancreas cancer cells and adjacent endothelium may block signaling from multiple growth factors to enhance apoptosis. The activation of the ras/MAP kinase pathway that occurs in up to 90 percent of pancreas cancer is the focus for novel approaches to radiation sensitization in Project 4. Investigators at Georgetown have developed a rafl antisense inhibitor that is already in Phase I trial and have developed other molecular targets in the pathway that are complementary. In addition, this SPORE is developing the infrastructure and resources to acquire tissues and bodily fluids from patients (Pancreatic Tumor Bank and Serum Detection & Molecular Identification Cores) with an expected 120 curative resections a year. The SPORE will utilize a biostatistical core to insure that all projects have appropriate designs, methods of analysis, and an integrated database for reporting patient outcomes. Further, the SPORE will support developmental projects designed to generate new knowledge and approaches to early detection and promote the development of career tracks dedicated to translational research in pancreatic cancer. This SPORE is also establishing interactions with SPOREs in other institutions as well as with other NCI- and NIH-funded programs to promote the aggressive development of novel therapies for the control of pancreas cancer.